Federal Register / Vol. 71, No. 249 / Thursday, December 28, 2006 / Notices 78215 

by forwarding the statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for 

entrance onto the NIH campus. All 

visitor vehicles, including taxicabs, 

hotel, and airport shuttles will be 

inspected before being allowed on 

campus. Visitors will be asked to show 

one form of identification (for example, 

a government-issued photo ID, driver’s 

license, or passport) and to state the 

purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nichd.nih.gov/about/nachhd.htm, 

where an agenda and any additional 

information for the meeting will be 

posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: December 19, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9885 Filed 12–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National 

Institute of Child Health and Human 

Development Special Emphasis Panel, 

Mentored Research Scientist 

Development Award. 

Date: January 5, 2007. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6100 Executive Boulevard, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person:Sathasiva B. 

Kandasamy, PhD., Scientific Review 

Administrator, Division of Scientific 

Review, National Institute of Child 

Health and Human Development, 6100 

Executive Boulevard, Room 5B01, 

Bethesda, MD 20892–9304, (301) 435–

6680, skandasa@mail.nih.gov. 

This notice is being published less 

than 15 days prior to the meeting due 

to the timing limitations imposed by the 

review and funding cycle. 

Name of Committee: National 

Institute of Child Health and Human 

Development Special Emphasis Panel, 

Mentored Patient-Oriented Research 

Career Development Award. 

Date: January 11, 2007. 

Time: 12 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6100 Executive Boulevard, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person:Sathasiva B. 

Kandasamy, PhD., Scientific Review 

Administrator, Division of Scientific 

Review, National Institute of Child 

Health and Human Development, 6100 

Executive Boulevard, Room 5B01, 

Bethesda, MD 20892–9304, (301) 435–

6680, skandasa@mail.nih.gov. 

This notice is being published less 

than 15 days prior to the meeting due 

to the timing limitations imposed by the 

review and funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: December 20, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9889 Filed 12–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, Drug Discovery. 

Date: January 3, 2007. 

Time: 3 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Mary Custer, PhD., 

Scientific Review Administrator, Center 

for Scientific Review, National Institutes 

of Health, 6701 Rockledge Drive, Room 

4180, MSC 7850, Bethesda, MD 20892, 

(301) 435–1164, custerm@csr.nih.gov. 

This notice is being published less 

than 15 days prior to the meeting due 

to the timing limitations imposed by the 

review and funding cycle. 

Name of Committee: Immunology 

Integrated Review Group, 

Transplantation, Tolerance, and Tumor 

Immunology Study Section. 

Date: January 24–25, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Radisson Clearwater Central, 

20967 US Highway 19 North, 

Clearwater, FL 33765. 

Contact Person: Cathleen L. Cooper, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 4208, MSC 7812, Bethesda, 

MD 20892, 301–435–3566, 

cooperc@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, Member Conflict: 

Psychopharmacology. 

Date: January 24–25, 2007. 

Time:9 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Christine L. Melchior, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 


sroberts on PROD1PC70 with NOTICES
78216 Federal Register / Vol. 71, No. 249 / Thursday, December 28, 2006 / Notices 

Drive, Room 5176, MSC 7844, Bethesda, 

MD 20892, 301–435–1713, 

melchioc@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated 

Review Group, Biodata Management 

and Analysis Study Section. 

Date: January 29, 2007. 

Time: 8:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Courtyard San 

Francisco Downtown, 299 Second 

Street, San Francisco, CA 94105. 

Contact Person: Marc Rigas, PhD., 

Scientific Review Administrator, Center 

for Scientific Review, National Institutes 

of Health, 6701 Rockledge Drive, Room 

4194, MSC 7826, Bethesda, MD 20892, 

301–402–1074, rigasm@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, Non-Viral Systems for Gene 

Transfer. 

Date: January 29, 2007. 

Time: 9:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Richard Panniers, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 2212, MSC 7890, Bethesda, 

MD 20892, (301) 435–1741, 

pannierr@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, PAR06–293 Quick Trial on 

Imaging and Image-guided Intervention. 

Date: February 2, 2007. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Eileen W. Bradley, 

DSC, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 5100, MSC 7854, Bethesda, 

MD 20892, (301) 435–1179, 

bradleye@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group, 

Neurotoxicology and Alcohol Study 

Section. 

Date: February 7–8, 2007. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Adam’s Mark Hotel, 1550 Court 

Place,, Denver, CO 80202. 

Contact Person: Joseph G. Rudolph, 

PhD, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 5186, MSC 7844, Bethesda, 

MD 20892, 301–435–2212, 

josephru@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group, Biological 

Rhythms and Sleep Study Section. 

Date: February 7, 2007. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Michael Selmanoff, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 3134, MSC 7844, Bethesda, 

MD 20892–7844, 301–435–1119, 

mselmanoff@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group, 

Neuroendocrinology, 

Neuroimmunology, and Behavior Study 

Section. 

Date: February 8–9, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Michael Selmanoff, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 3134, MSC 7844, Bethesda, 

MD 20892, 301–435–1119, 

mselmanoff@csr.nih.gov. 

Name of Committee: Cardiovascular 

Sciences Integrated Review Group, 

Clinical and Integrative Cardiovascular 

Sciences Study Section. 

Date: February 8–9, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Madison Hotel, 1177 15th 

Street, NW., Washington, DC 20005. 

Contact Person: Russell T. Dowell, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 4128, MSC 7814, Bethesda, 

MD 20892, (301) 435–1850, 

dowellr@csr.nih.gov. 

Name of Committee: Molecular, 

Cellular and Developmental 

Neuroscience Integrated Review Group, 

Synapses, Cytoskeleton and Trafficking 

Study Section. 

Date: February 8–9, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Jonathan K. Ivins, 

PhD, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of health, 6701 Rockledge 

Drive, Room 4040A, MSC 7806, 

Bethesda, MD 20892, (301) 594–1245, 

uvubsh@csr.nih.gov. 

Name of Committee: Genes, Genomes, 

and Genetics Integrated Review Group, 

Molecular Genetics B Study Section. 

Date: February 8–9, 2007. 

Time:8 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Pier 5 Hotel, 711 Eastern 

Avenue, Baltimore, MD 21202. 

Contact: Richard a. Currie, PhD, 

Scientific Review Administrator, Center 

for Scientific Review, National Institutes 

of Health, 6701 Rockledge Drive, Room 

5128, MSC 7840, Bethesda, MD 20892, 

(301) 435–1219, currieri@csr.nih.gov. 

Name of Committee: Biology of 

Development and Aging Integrated 

Review Group, Development—2 Study 

Section. 

Date: February 8–9, 2007. 

Time: 8 am to 5 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: The River Inn, 924 25th Street, 

Washington, DC 20037. 

Contact Person: Neelakanta 

Ravindranath, PhD., MVSC., Scientific 

Review Administration, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 

5140, MSC 7843, Bethesda, MD 20892, 

301–435–1034, ravindrn@csr.nih.gov. 

Name of Committee: Health of the 

Population Integrated Review Group, 

Community Influences on Health 

Behavior. 

Date: February 8–9, 2007. 

Time: 8:30 am to 5 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Washington, DC, 

1400 M Street, NW, Washington, DC 

20005. 

Contact Person: Ellen K. Schwartz, 

Edd., Scientific Review Administrator, 

Center for Scientific Review National 

Institutes of Health, 6701 Rockledge 

Drive, Room 3168, MSC 7770, Bethesda, 

MD 20892, 301–435–0681, 

schwarte@csr.nih.gov. 

Name of Committee: Genes, Genomes, 

and Genetics Integrated Review Group, 

Genetics of Health and Disease Study 

Section. 

Date: February 12–13, 2007 

Time: 9 am to 2:30 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Hotel, 5151 

Pooks Hill Road, Bethesda, MD 20814. 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 249 / Thursday, December 28, 2006 / Notices 78217 

Contact Person: Cheryl M. Corsaro, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 2204, MSC 7890, Bethesda, 

MD20892, (301) 435–1045, 

corsaroc@nih.gov. 

Name of Committee: Respiratory 

Sciences Integrated Review Group, Lung 

Cellular, Molecular, and 

Immunobiology Study Section. 

Date: February 15–16, 2007. 

Time: 8 am. to 3 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: M Street Hotel, 1143 New 

Hampshire Ave., NW, Washington, DC 

20037. 

Contact Person: George M. Barnas, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 2810, MSC 7818, Bethesda, 

MD 20892, 301–435–0696, 

barnasg@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, Mosquito Vectors. 

Date: February 15, 2007. 

Time: 1 pm. to 4 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Fouad A. El-Zaatari, 

PhD., Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge 

Drive, Room 3206, MSC 7808, Bethesda, 

MD 20814–9692, (301) 435–1149, 

elzaataf@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel, Social Science and Population 

Studies R03s, R15s, and R21s. 

Date: February 16 2007. 

Time: 8 am to 5 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: Marina Del Rey Hotel, 13534 

Bali Way, Marina Del Rey, CA 90292. 

Contact Person: Valerie Durrant, PhD., 

Scientific Review Administrator, Center 

for Scientific Review, National Institutes 

of Health, 6701 Rockledge Drive, Room 

3418, MSC 7770, Bethesda, MD 20892. 

(301) 435–3554, durrantv@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 20, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9887 Filed 12–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Convection Enhanced 

Delivery and Tracking of Gadolinium 

Conjugated Therapeutic Agents to the 

Central Nervous System 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

worldwide license to practice the 

invention embodied in: HHS. Ref. No. 

E–202–2002 ‘‘Method for Convection 

Enhanced Delivery of Therapeutic 

Agents,’’ Provisional Patent 

Application, 60/413,673; International 

Patent Application PCT/US03/30155, 

U.S. Patent Application Serial No. 10/ 

528,310; European Patent Application 

Serial No. 03756863.1; Australian Patent 

Application No. 2003299140; Canadian 

Patent Application No. 2,499,573; and 

HHS Ref. No. E–206–2000/0 and /1 

‘‘Method for Increasing the Distribution 

of Therapeutic Agents;’’ and ‘‘Method 

for Increasing the Distribution of 

Nucleic Acids;’’ Provisional Patent 

Application 60/250,286; Provisional 

Patent Application No. 60/286,308; U.S. 

Patent Application No. 09/999,203; U.S. 

Patent Application No. 10/132,681; and 

Canadian Patent Application No. 

2327208, to Medtronic Neurological, a 

Division of the Medtronic Corporation, 

having its headquarters in Minneapolis, 

Minnesota. The United States of 

America is the assignee of the patent 

rights of the above invention. The 

contemplated exclusive license may be 

granted in a field of use limited to the 

development and sales of a clinical 

grade surrogate tracer for tracking the 

distribution of convection enhanced 

delivered central nervous system 

therapeutics, excluding lipid based 

systems. 

DATES: Only written comments and/or 

applications for a license received by 

the NIH Office of Technology Transfer 

on or before February 26, 2007 will be 

considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Michael A. Shmilovich, Esq., Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

5019; Facsimile: (301) 402–0220; E-mail: 

shmilovm@mail.nih.gov. A signed 

confidentiality nondisclosure agreement 

will be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: The patent 

applications intended for licensure 

disclose and/or cover the following: 

E–202–2002 ‘‘Method for Convection 

Enhanced Delivery of Therapeutic 

Agents’’

The invention is a method for 

monitoring the spatial distribution of 

therapeutic substances by MRI or CT 

that have been administered to tissue 

using convection enhanced delivery, a 

technique that is the subject of NIHowned U.S. Patent No. 5,720,720. In one 

embodiment, the tracer is a molecule, 

detectable by MRI or CT, which 

functions as a surrogate for the motion 

of the therapeutic agent through the 

solid tissue. In other particular 

embodiments, the tracer is the 

therapeutic agent conjugated to an 

imaging moiety. The method of this 

invention uses non-toxic 

macromolecular MRI contrast agents 

comprised of chelated Gd(III). In 

particular, the surrogate tracer used in 

this invention is a serum albumin 

conjugated with either a gadolinium 

chelate of 2-(p-isothiocyanotobenzyl)-6- 

methyldiethylenetriamine pentaacetic 

acid or with iopanoic acid. These 

macromolecular imaging agents have 

clearance properties that mimic the 

pharmacokinetic properties of coadministrated drugs, so as to be useful 

in quantifying the range and dosage 

level of therapeutic drugs using MR 

imaging. 

E–206–2000 ‘‘Method for increasing the 

distribution of therapeutic agents;’’

‘‘Method for increasing the distribution 

of nucleic acids’’

The invention pertains to the reliance 

of therapies on the local parenchymal 

delivery of macromolecules or nucleic 

acids for success. However, the volume 

of distribution of many of these 

potential therapeutic agents is restricted 

by their interactions with the 

extracellular matrix and cellular 

receptors. Heparin-sulfate proteoglycans 


sroberts on PROD1PC70 with NOTICES